Home Featured Page 186

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Core One Labs’ Upgrades to OTCQB Venture Market

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment...

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to...

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million...

HAVN Life To Be Featured On Viewpoint with Dennis Quaid

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health...

PT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women,...

Stephen Bardin to Join atai Life Sciences as CFO Designate

Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Core One Labs’ Upgrades to OTCQB Venture Market

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment...

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to...

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million...

HAVN Life To Be Featured On Viewpoint with Dennis Quaid

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health...

PT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women,...

Stephen Bardin to Join atai Life Sciences as CFO Designate

Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY